|  |  |
| --- | --- |
| **Reviewer:**  | Choose an item.  |
| **Title:** |       |
| **Last name of the first author & year published:** |       |
| **Language:** | Choose an item. Other:       |

|  |
| --- |
| **Criteria for exclusion (only need to have ONE criteria present to exclude):** |
| Study design | ANY of the following[ ]  Observational study with a control group (e.g. cohort or case-control)[ ]  No independent control group (e.g. case report or case series)[ ]  Review (please keep systematic reviews separately for reference list checking)[ ]  Other type of publication (i.e. not a clinical study) |
| Population | ANY of the following[ ]  Patients without a confirmed diagnosis of partial epilepsy[ ]  Patients with and without partial epilepsy considered together (unless results for patients with partial epilepsy are reported separately) e.g. multiple epilepsy diagnoses in the same study[ ]  Pediatric patients (majority of patients less than 18 years old, unless reported as a subgroup) |
| Intervention | ANY of the following[ ]  Lacosamide in BOTH arms of the study, unless there are multiple arms comparing another antiepileptic or placebo against different doses of lacosamide[ ]  Single-dose or short-term lacosamide therapy for an acute seizure disorder  |

|  |
| --- |
| **Criteria for inclusion – see specific instructions below for which criteria are mandatory for inclusion** |
| Study design | [ ]  MUST be a Randomized controlled trial |
| Population | [ ]  Adult patients (majority of patients over the age of 18), hospitalized or not, with a clinical diagnosis of partial-onset seizures (with or without secondary generalization) |
| Interventions in experimental or control groups | [ ]  MUST include lacosamide (intravenous or oral or a combination of both) **AND** ONE of the following as a comparator:[ ]  any other antiepileptic[ ]  placebo |
| Outcomes | ANY one of the following outcomes are reported[ ]  Change in seizure frequency from baseline[ ]  Responder rate at (proportion of patients with a 50% or greater reduction in seizure frequency in the treatment period compared to the pre-randomization baseline period)[ ]  Discontinuation of study drug due to adverse effects[ ]  Proportion of patients that were seizure-free during the treatment period[ ]  Adverse effects including: Ataxia, dizziness, fatigue, headache, nausea and somnolence[ ]  Serious adverse effects[ ]  Hospital admission[ ]  Length of hospital stay[ ]  Length of stay in a specialized epilepsy unit[ ]  Quality of life as reported by standardized scoring instruments (e.g. Quality of life inventory in epilepsy – QOLIE-31 scale, Seizure Severity Scale – SSS, Patient Global Impression of Change – PGIC scale)[ ]  Economic outcomes as captured by the search strategy (drug costs, hospitalization costs, caregiver costs, caregiver time) |

|  |  |
| --- | --- |
| **[ ]  TO BE INCLUDED** |  |
| **[ ]** FURTHER ACTION REQUIRED | What action: |
| **[ ]  TO BE EXCLUDED** REASON: | [ ]  Non-randomized study design[ ]  Patients without a diagnosis of partial epilepsy[ ]  Pediatric patients[ ]  Lacosamide – single dose or short-term therapy[ ]  Outcomes – none of relevance to review/or clinically importantOther: |

Additional comments: